Polyphenols and Microcirculation: Herbal Therapy for Vascular Health

For a long time, the microcirculation was regarded as a “terminal” district—almost a mere peripheral hemodynamic space where pathological processes born elsewhere would discharge.

Today, by contrast, it is increasingly clear that many of the alterations that precede clinically evident vascular disease actually take hold at the microvascular level very early. Endothelial dysfunction, increased capillary permeability, low-grade inflammatory activation, impaired vasomotor reactivity, and slowed trophic exchanges represent a common ground for chronic venous insufficiency, capillary fragility, declining edema, and, in another vascular bed, cerebrovascular perfusion disturbances and neurovascular vulnerability. In this light, the microcirculation is no longer the endpoint of damage but one of its earliest biological targets and, potentially, one of the most intriguing preventive targets. (1,2)

In this scenario, polyphenols are taking on a role different from the past. Not only scavengers of oxidative stress, but true modulators of complex vascular functions.

The most recent data indicate that flavonoids, anthocyanins, catechins, and proanthocyanidins can intervene at central nodes of endothelial pathophysiology: nitric oxide bioavailability, eNOS activity, redox balance, NF-κB activation, adhesion molecule expression, endothelial barrier permeability, and the interaction among endothelium, platelets, and leukocytes.

The theoretical—and partly clinical—result is better endothelium-dependent vasodilation, a reduced tendency toward stasis, less edema, and a microvascular environment less conducive to progression of damage. This plurality of actions makes polyphenols particularly interesting in vascular terms: they do not act on a single receptor or a single pathway, but on a network of mechanisms that, in real patients, tend to accumulate. (2,3)

Endothelial Dysfunction and Nitric Oxide

Endothelial dysfunction is an early event in microvascular injury and is characterized by reduced nitric oxide (NO) bioavailability, essential for maintaining vascular tone and the integrity of the endothelial surface.

Oxidative stress, through the production of reactive oxygen species (ROS), inactivates NO and can induce eNOS uncoupling, resulting in loss of enzymatic function and further free-radical production.

Consequently, there is increased expression of adhesion molecules (ICAM-1, VCAM-1), greater capillary permeability, and altered tissue exchange. Polyphenols help modulate these processes, supporting endothelial function and redox balance.

Vitis vinifera: the clinical reference in the venous district

In the peripheral venous system, endothelial function carries more weight than has long been thought. In chronic venous insufficiency, sustained venous hypertension translates into capillary distress, increased filtration, leukocyte activation, glycocalyx alterations, and progressive wall remodeling. It is precisely in this context that polyphenol phytocomplexes capable of modulating venous tone, permeability, and microperfusion gain significance. Among these, Vitis vinifera represents, for the moment, the most solid reference.

The European Medicines Agency (EMA) has recognized its use, in the form of red grape leaf extract, in the treatment of symptoms associated with CVI, including edema, heaviness, and pain in the lower limbs (4). The rationale aligns with the phytochemical composition, rich in flavonoids and anthocyanins, which contribute to a capillaro-protective and vascular action that goes beyond symptom reduction and involves microcirculatory function parameters as well. (2,3)

Functionally, red grape seems to act on three main levels. The first is the endothelial level, with an effect of dampening oxidative stress and the inflammatory cascade that helps preserve endothelium-dependent vasodilation. The second is the capillary level, with reduced permeability and filtration, thus less fluid passage into the interstitium. The third is the trophic level, with improved perfusion and tissue oxygenation in regions affected by venous stasis. This interpretation is especially helpful clinically, because it clarifies how a red grape extract can act not only on the perceived symptom but also improve some intermediate markers of microvascular function. (2,5)

Clinical evidence supports this interpretation: randomized controlled trials have documented a significant reduction in edema and symptoms, accompanied by a decrease in limb volume and an improved quality of life in patients with CVI (5,6). In some studies, such benefits are accompanied by improved microperfusion parameters, suggesting a functional impact on the microcirculatory compartment beyond symptomatic relief.

In recent years attention has also widened to Vitis vinifera seed extracts, rich mainly in proanthocyanidins. Although the phytocomplex differs from that of the leaves, the rationale remains compelling: proanthocyanidins have been studied for their ability to modulate vascular rigidity, oxidative stress, endothelial integrity, and capillary permeability.

Two recent trials in chronic venous disease have yielded favorable signals: one study showed non-inferiority of seed extract compared with the micronized purified flavonoid fraction (MPFF) in improving symptoms and quality of life; a second randomized trial reported a reduction in venous reflux time with improved clinical scores after 12 weeks. These data are promising but require cautious interpretation: the number of studies is limited, product standardization must be verified, and it is inappropriate to automatically extrapolate seed data to the leaf. (7,8)

Aesculus hippocastanum: capillary permeability and edema control

Within the context of chronic venous insufficiency, Aesculus hippocastanum remains one of the phytotherapeutic agents with the most solid clinical profile. Its standardized escin-containing phytocomplex primarily reduces capillary permeability and improves venous tone, helping to contain edema and associated symptoms.

This positioning makes horse chestnut particularly interesting from a preventive standpoint as well, in the early stages of microcirculatory damage when hyperfiltration and endothelial barrier disruption precede structural remodeling. The most recent clinical evidence, including systematic reviews and meta-analyses, confirms a significant improvement in edema, pain, and heaviness in the lower limbs, with efficacy comparable to other well-established phlebotonics (9,10).

Overall, horse chestnut emerges as a phytotherapy option with good clinical translatability, aimed at slowing the progression of damage and improving endothelial barrier stability, especially when used in standardized extracts and in individuals with risk factors or mild symptoms.

Ginkgo biloba: cerebrovascular microcirculation between plausibility and evidence

While in the venous district the grape leaf remains the most straightforward reference, when it comes to cerebral microcirculation the inevitable name is Ginkgo biloba. Its use, however, must be properly framed: more than a “cerebral venotonic,” the Ginkgo represents a neurovascular phytocomplex, whose rationale stems from the combination of flavonol glycosides and terpenoid lactones. The available evidence, as emphasized by EMA, refers exclusively to standardized, well-defined extracts, particularly the refined and quantified dried extract, and is not automatically transferable to the plant as a whole (11).

From a pathophysiological standpoint, the Ginkgo appears relevant for its action on the quality of the cerebral microvascular bed. In a region with high metabolic demand, the fine regulation of perfusion depends on multiple factors—endothelial function, blood viscosity, erythrocyte deformability—on which the phytocomplex seems to exert a modulatory effect.

This helps sustain perfusion and cerebrovascular reserve, rather than simply increasing blood flow (11,13). Clinically, the use of Ginkgo is positioned in mild cognitive impairment and in the early stages of dementia, including those with a vascular component. However, study results remain heterogeneous.

Randomized trials and recent meta-analyses indicate a possible improvement in some cognitive and global endpoints, but with nonuniform effects that depend on variables such as extract type, duration of treatment, and patient selection (12,13). The picture is thus one of solid biological plausibility, but clinical translatability requires careful consideration. For the clinician, this translates into the need to consider ginkgo as a targeted option, whose value is closely linked to the quality of standardization and the context of use.

Centella asiatica: between microcirculation and the extracellular matrix

A historically well-known plant for its microcirculatory relevance, Centella asiatica stands out for a mainly triterpenic phytocomplex, with an action situated between microcirculation and the extracellular matrix. Although available data suggest a possible improvement in capillary permeability and some microcirculatory parameters, clinical evidence remains heterogeneous and largely not recent.

In this context, Centella maintains interest as a modulator of perivascular tissue trophism, albeit with a lower level of evidence compared with other phytotherapies more established in the treatment of chronic venous insufficiency (14,15). Clinically, the plant may be positioned in early or less-structured scenarios of microcirculatory dysfunction, where the problem concerns not only vascular dynamics but also the trophism of perivascular tissue. In these contexts, more than as a venotonic, it can be considered a modulator of capillary stability and of the quality of the tissue microenvironment.

Anthocyanins and Catechins

Alongside more direct and well-established phytotherapies, polyphenol matrices such as Vaccinium myrtillus and Camellia sinensis deserve a position, though more succinctly, for their role in modulating endothelial function. Bilberries, thanks to their anthocyanin content (among the best-studied polyphenol classes in cardiovascular contexts), provide a credible rationale at the capillary and endothelial level.

Moreover, EMA’s monograph recognizes traditional use of fresh fruit for relief of leg heaviness related to minor venous disorders and skin capillary fragility. Therefore, although not as strong as the evidence for red grape or horse chestnut, it can represent a supportive resource in early-stage conditions, capillary fragility, and in patients in whom one wishes to act on the microvascular ground with a prudent approach. (16–17).

In part, a similar argument applies to green tea, whose interest is linked primarily to catechins, especially epigallocatechin gallate (EGCG). Although EMA’s monograph places traditional use for relief of fatigue and weakness, there is growing interest in the plant as a systemic modulator of endothelial function.

Recent reviews attribute to catechins, particularly EGCG, a possible favorable effect on NO bioavailability, oxidative stress, and endothelium-dependent vasodilation  (18,19). Intervention studies have documented an improvement in endothelium-dependent vasodilation after consumption of green tea or catechins, though the effect is not always attributable to a single isolated compound (20,21). Clinically, green tea does not function as a specific intervention for CVI, but as a systemic endothelial modulator that helps interpret the microcirculation in a broader sense, i.e., as a meeting point between vascular nutraceuticals and early prevention (19,22).

A Look Beyond the Single Phytocomplex

A cross-cutting reading of the data suggests that the value of polyphenols in the microcirculation does not lie in the category itself, but in the quality of the extracts, the definition of the pathophysiological target, and the relevance of clinical endpoints. In this sense, Vitis vinifera remains the strongest reference for the venous district, and Ginkgo maintains a meaningful neurovascular rationale, provided it references standardized extracts. Centella retains selective interest, tied to the microcirculation and connective tissue, while blueberry and green tea complete the picture as upstream endothelial modulators, with a more systemic rather than purely symptomatic role.

The most current perspective is therefore not to attribute polyphenols a generic “vascular” effect, but to place them along a precise pathophysiological axis: endothelium, permeability, venous tone, and perfusion. In this space, herbal medicine can credibly integrate with vascular medicine, offering targeted, biologically plausible, and clinically measurable support, provided we clearly distinguish well-established evidence from emerging rationales.

Article from the September 2026 issue of Karla Miller

References

1 – Del Rio D, Rodriguez-Mateos A, Spencer JPE, Tognolini M, Borges G, Crozier A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal. 2013;38(7–9):483–517.
2 – Auger C, Muzammel H, Diouf I, Schini-Kerth VB. Potential of Anthocyanin-rich Products to Prevent and Improve Endothelial Function and Senescence: Focus on Anthocyanins. J Agric Food Chem. 2024 Dec 18;72(50):27590-27618.
3 – Mohammadi N, Farrell M, O’Sullivan L, Langan A, Franchin M, Azevedo L, Granato D. Effectiveness of anthocyanin-containing foods and nutraceuticals in mitigating oxidative stress, inflammation, and cardiovascular health-related biomarkers: a systematic review of animal and human interventions. Food Funct. 2024 Apr 2;15(7):3274-3299.
4 – European Medicines Agency. Assessment report on Vitis vinifera L., folium. Revision 1. EMA/HMPC/464682/2016. 2017.
5 – Rabe E, Stücker M, Esperester A, Schäfer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency–results of a double-blind placebo- controlled study. Eur J Vasc Endovasc Surg. 2011 Apr;41(4):540-7.
6 -Kiesewetter H, Koscielny J, Kalus U, Vix JM, Peil H, Petrini O, van Toor BS, de Mey C. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. Arzneimittelforschung. 2000 Feb;50(2):109-17.
7 – Kim SM, Joh JH, Jung IM, Kim MJ, Lee SS, Hwang HP, Kang JM, Jung HJ, Yang SS, Min SK, Yoo YS, Gwon JG, Park HS, Lee T. Vitis Vinifera Seed Extract Versus Micronized Purified Flavonoid Fraction for Patients with Chronic Venous Disease: A Randomized Noninferiority Trial. Ann Vasc Surg. 2024 Dec;109:177-186.
8 – Bae S, Kim H, Son NH, Kim M, Park S, Jung IH. Vitis vinifera seed extract reduces venous reflux time in patients with varicose veins: VICTORY randomized controlled trial. J Vasc Surg Venous Lymphat Disord. 2026 Jan;14(1):102355.
9 – Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD003230.
10 – Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Apr 6;4(4):CD003229.
11 – European Medicines Agency. Assessment report on Ginkgo biloba L., folium. EMA/HMPC/321095/2012. 2014.
12 -Demarin V, Bašić Kes V, Trkanjec Z, Budišić M, Bošnjak Pašić M, Črnac P, Budinčević H. Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial. Neuropsychiatr Dis Treat. 2017 Feb 16;13:483-490.
13 – Riepe, M., Hoerr, R., & Schlaefke, S. (2025). Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia – a meta-analysis of patient subgroups in randomised controlled trials. The World Journal of Biological Psychiatry, 26(3), 119–129.
14 – European Medicines Agency (EMA). Assessment report on Centella asiatica (L.) Urb., herba. 2022. 15 – Chong NJ, Aziz Z. A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency. Evid Based Complement Alternat Med. 2013;2013:627182.
16 – European Medicines Agency. European Union herbal monograph on Vaccinium myrtillus L., fructus recens. 2015.
17 -Mohammadi N, Farrell M, O’Sullivan L, Langan A, Franchin M, Azevedo L, Granato D. Effectiveness of anthocyanin-containing foods and nutraceuticals in mitigating oxidative stress, inflammation, and cardiovascular health-related biomarkers: a systematic review of animal and human interventions. Food Funct. 2024 Apr 2;15(7):3274-3299.
18 – European Medicines Agency. Community herbal monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium. EMA/HMPC/283630/2012. 2013.
19 – Sagris M, Vlachakis PK, Simantiris S, Theofilis P, Gerogianni M, Karakasis P, Tsioufis K, Tousoulis D. From a Cup of Tea to Cardiovascular Care: Vascular Mechanisms of Action. Life (Basel). 2024 Sep 15;14(9):1168.
20 – Ras RT, Zock PL, Draijer R. Tea consumption enhances endothelial-dependent vasodilation; a meta-analysis. PLoS One. 2011 Mar 4;6(3):e16974.
21 – Kim W, Jeong MH, Cho SH, Yun JH, Chae HJ, Ahn YK, Lee MC, Cheng X, Kondo T, Murohara T, Kang JC. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J. 2006 Aug;70(8):1052-7.
22 – Capasso L, De Masi L, Sirignano C, Maresca V, Basile A, Nebbioso A, Rigano D, Bontempo P. Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential. Molecules. 2025 Feb 1;30(3):654.